Atorvastatin

Catalog No.S5715

For research use only.

Atorvastatin is a lipid lowering agent. It is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. Atorvastatin activates autophagy.

Atorvastatin Chemical Structure

CAS No. 134523-00-5

Selleck's Atorvastatin has been cited by 12 Publications

Purity & Quality Control

Choose Selective HMG-CoA Reductase Inhibitors

Biological Activity

Description Atorvastatin is a lipid lowering agent. It is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. Atorvastatin activates autophagy.
In vitro

Atorvastatin, one of the statins, inhibits the c-Myc pathway in chronic myeloid leukemia (CML) cells, demonstrating that c-Myc is a target of statins.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NVvQfnBNTnWwY4Tpc44h[XO|YYm= MoTvWHBgXFKDTmPQU3JVTVJ8IIXweIFs\SCrbjDPRXRROUJzLXX4dJJme3OrbnegTGVMOjl|IHPlcIx{NCCNbU2xNk41|ryP NIjT[HQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUm3NFc6QSd-MUW5O|A4QTl:L3G+
L6 NX\acIlNTnWwY4Tpc44h[XO|YYm= MWLJcohq[mm2aX;uJI9nKGOqb3zld5Rmem:uIIP5cpRp\XOrczDpckBz[XRiTE[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kd3Kyb4LheIlwdiCxZjDbNVREZWGlZYTheIUhcW62bzDjbI9t\XO2ZYLvcEwhUUN3ME2wMlA4QM7:TR?= NFLaUWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESxNlMyPyd-MUi0NVI{OTd:L3G+
C2C12 NH3HSpRHfW6ldHnvckBie3OjeR?= M1zwN|EhfU1? MYTJcoR2[3Srb36gc4Yh[2WubDDkbYZn\XKnboTpZZRqd25iaX6gcY92e2ViQ{LDNVIh[2WubIOgZZN{\XO|ZXSgZZMhdXmxc3nuJIhm[X[7IHPoZYlvKGW6cILld5Nqd25iYYSgNUB2VQ>? M4C2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEixPFU2Lz5{MEC4NVg2PTxxYU6=
HepG2 MmHvSpVv[3Srb36gZZN{[Xl? NGi3emsyKHWP NV3iVWc3XXC{ZXf1cIF1cW:wIH;mJGxFVCC{ZXPldJRweiCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF1KDFidV2gbY4heHKnc3XuZ4Uhd2ZiQWLIMZNx\WOrZnnjJJNqWk6D NVHPUIZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOVYxQThpPkKwN|U3ODl6PD;hQi=>
HEK293 NXXnS41iTnWwY4Tpc44h[XO|YYm= NVHseYtRSWO2aY\peJkh[XRiaIXtZY4hdGm4ZYKgU2FVWDGEMzDlfJBz\XO|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyxiS329NE44O87:TR?= NGryXIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
HEK293 MWrGeY5kfGmxbjDhd5NigQ>? M1PQbGFkfGm4aYT5JIF1KGi3bXHuJIxqfmW{IF;BWHAySjFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMtKEuvPUCuO|fPxE1? NXOyO|NHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFExPjhpPkKyOVQyODZ6PD;hQi=>
HEK293 M2Lvd2Z2dmO2aX;uJIF{e2G7 NWfSNmVXSWO2aY\peJkh[XRiaIXtZY4hdGm4ZYKgU2FVWDKEMTDlfJBz\XO|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyxiS329Nk45PM7:TR?= NIHJNI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
HEK293 MYDGeY5kfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKE:DVGCxRlEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIHXzeJJi\GmxbD2xO4JmfGFvZ3z1Z5Vzd26rZHWgd5Vje3S{YYTlMEBKSzVyPUCuOu69VQ>? M4n3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUi3PVg3Lz5{MkW4O|k5PjxxYU6=
HEK293 NXzaPWVkTnWwY4Tpc44h[XO|YYm= NVW2OHZtUW6qaXLpeIlwdiCxZjDPRXRROUJzIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC3c3nu[{BxcXSjdnHzeIF1cW5ic4Xid5Rz[XSnLDDJR|UxRTBwON88US=> M13wVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUi3PVg3Lz5{MkW4O|k5PjxxYU6=
HEK293 NE\ySI5HfW6ldHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKE:DVGCxRlEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJV{cW6pIHXzeJJwdmVvMz3zeYxn[XSnIIP1ZpN1emG2ZTygTWM2OD1zLkdOwG0> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV6N{m4Okc,OjJ3OEe5PFY9N2F-
hepatocytes MknsSpVv[3Srb36gZZN{[Xl? M4fvVlAvOSC2bzCxNEB2VQ>? NHu3PXJ2eCC2bzC5NEBucW6| MoG3SJJ2\yCvZYThZo9tcXOvIHnuJHNxemGpdXWtSIF4dGW7IILheEBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgNVAoPiClZXzsd{BifCByLkGgeI8hOTBidV2geZAhfG9iOUCgcYlveyCkeTDt[YRq[S2ub4PzJI1mfGixZDygT40:OC52M988US=> M{DxW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUmzNFM5Lz5{MkW5N|A{QDxxYU6=
hepatocytes MXjGeY5kfGmxbjDhd5NigQ>? MoPnNE4yKHSxIEGwJJVO Ml3zeZAhfG9iOUCgcYlvew>? Ml:0SJJ2\yCvZYThZo9tcXOvIHnuJHNxemGpdXWtSIF4dGW7IILheEBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgNVAoPiClZXzsd{BifCByLkGgeI8hOTBidV2geZAhfG9iOUCgcYlveyCkeTDjc453\W62aX;uZYwh[XO|YYmsJGtuRTFwM988US=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV7M{CzPEc,OjJ3OUOwN|g9N2F-
A549 NX76UHlZS3m2b4TvfIlkcXS7IHHzd4F6 M3nse|czKGi{cx?= MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OD63{txO NGDNUGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3NFU1Oid-MkO1O|A2PDJ:L3G+
HS68 NYjxRWpMS3m2b4TvfIlkcXS7IHHzd4F6 M1LzPFczKGi{cx?= NHS4OHFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJWzZ6IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlIvP87:TR?= NXnMflB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O|A2PDJpPkKzOVcxPTR{PD;hQi=>
MEF MlHXR5l1d3SxeHnjbZR6KGG|c3H5 NGLTOIQ4OiCqcoO= NYfLO|NKS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVUWIIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N|AvP87:TR?= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5MEW0Nkc,OjN3N{C1OFI9N2F-
HepG2 NYfPXIRUTnWwY4Tpc44h[XO|YYm= M4\mNFExKHWP MlHiTY5lfWO2aX;uJI9nKFOURVLQNkBu[XS3cnH0bY9vKGmwIHj1cYFvKEincFeyJINmdGy|IHH0JFExKHWPIHHmeIVzKG:4ZYLubYdpfCCrbnP1ZoF1cW:wIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6NEmzOkc,OjZ5OES5N|Y9N2F-
human red blood cells NGLYTGNCdnSrcHzhd41w\GmjbDDhd5NigQ>? NIqxdI81QCCqcoO= M3\KUWFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IHHnZYlve3RiY3jsc5JweXWrbnWtdoV{cXO2YX70JHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCZMjDpcoZm[3SnZDDpckBpfW2jbjDy[YQh[myxb3SgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFO\QmKgeIV{fCxiSVO1NF0yOC5|zszN MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6OEOwN{c,OjZ7OEizNFM9N2F-
Hep3G NFH5XJNHfW6ldHnvckBie3OjeR?= NWTSR5psOjVidV2= NHX3b4k1QCCqcoO= NE\afVNKdmirYnn0bY9vKG:oIFjNS{BEd0FicnXkeYN1[XOnIHnuJIh2dWGwIFjldFNIKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIFzEUEBz\WOncITvdkBmgHC{ZYPzbY9vKGG2IEK1JJVOKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JIludXWwb3\seY9z\XOlZX7j[UBu\XSqb3S= NX\kNppIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GwNFU{PjdpPkOxNFA2OzZ5PD;hQi=>
A549 MUHGeY5kfGmxbjDhd5NigQ>? MWLS[YR2[3Sjc3WgRYN1cX[rdImgRZN{[Xl8IGTo[UBJVUeUIHHjeIl3cXS7IIfhd{Bx\XKob4Lt[YQhfXOrbnegTG1INUOxQTDy[YR2[3Sjc3WgZZN{[Xlia3n0JIZzd21iU3nncYEuSWymcnnjbEB4cXSqIITo[UBpfW2jbjDy[YNwdWKrbnHueEBxem:2ZXnuJI9zKDFyMDFOwIchfG:2YXygZ4VtdCCueYPheIV{KG[{b32gRVU1QSClZXzsd{4hVG:4YYP0ZZRqdiC5YYOgeZNm\CCjczDhJJBwe2m2aY\lJINwdnS{b3ysJIFv\CCVQVjBJIF{KGFibnXnZZRqNCCLQ{WwQVAvODFzNt88US=> NFi5NYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDh5Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Growth inhibition assay Cell viability 24815071
Western blot PDX-1 / BETA2 / NeuroD 30863781
In vivo

ATV-Exos activates AKT/eNOS signaling pathway to augment the angiogenesis of endothelial cells via upregulating miR-211-3p, thereby resulting in accelerated wound regeneration of the diabetic rats.[2]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: murine CML-KLS+ cells, OP-9 stromal cells
  • Concentrations: 2 μM
  • Incubation Time: 3 days
  • Method:

    CML cKit+Lineage Sca1+ (KLS) cells are isolated from CML mice. Thereafter, the effect of statins on the colony-forming capacity of CML-KLS cells is determined. Freshly isolated CML-KLS cells are co-cultured with OP-9 stromal cells in the presence of IM (1 M), DA (0.5 M), and rosuvastatin (2 M) or atorvastatin (2 M) for 72 h. Thereafter, the cells are washed with PBS and transferred to semi-solid medium. The number of colonies is counted under the microscope.

Animal Research:

[2]

  • Animal Models: Sprague-Dawley rats ofdiabetes models
  • Dosages: 50 μg/mL
  • Administration: s.c

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 558.64
Formula

C33H35FN2O5

CAS No. 134523-00-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04915183 Not yet recruiting Drug: Atorvastatin|Other: Placebo Hearing Loss|Head and Neck Cancer National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC) August 3 2022 Phase 3
NCT05464628 Recruiting Drug: Atorvastatin|Drug: ASC42 Healthy Gannex Pharma Co. Ltd. July 6 2022 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Atorvastatin | Atorvastatin supplier | purchase Atorvastatin | Atorvastatin cost | Atorvastatin manufacturer | order Atorvastatin | Atorvastatin distributor